Today: September 11, 2024
Today: September 11, 2024

Obesity

Europe|Health

EU regulator backs use of Novo's Wegovy to lower heart risks

The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes, the Danish drugmaker said on

EU regulator backs use of Novo's Wegovy to lower heart risks
Health|Lifestyle

The health movement to save black women

African American women are reclaiming their health and their communities by walking with the nonprofit GirlTrek. 

The health movement to save black women
Business

Eli Lilly's head of diabetes and obesity unit to retire

Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.

Eli Lilly's head of diabetes and obesity unit to retire
News

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey

The number of U.S. employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a

U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
Business|Health

Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds

A new study finds that the medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight

Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds
Business

Analysis-Healthcare companies counter investor worries over Wegovy effect

Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't

Analysis-Healthcare companies counter investor worries over Wegovy effect
Business

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
Business

Eli Lilly: still seeking UK approval on pen for weight-loss drug

Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and

Eli Lilly: still seeking UK approval on pen for weight-loss drug
World

How well-off Brits still buy Ozempic online for weight loss

John, a tech executive who has been battling weight gain since his 30s, has a nine-month supply in his refrigerator.

How well-off Brits still buy Ozempic online for weight loss
World

Novo Nordisk to launch obesity drug Wegovy in Japan in February

Novo Nordisk said on Thursday it will launch its hugely popular Wegovy obesity drug in Japan on Feb. 22 next year.

Novo Nordisk to launch obesity drug Wegovy in Japan in February
Business|Health|News

New weight loss drugs are out of reach for millions of older Americans because Medicare won't pay

Obesity drugs like Wegovy and Zepbound are capturing the attention of celebrities and showing promising results in helping people shed pounds

New weight loss drugs are out of reach for millions of older Americans because Medicare won't pay
Health

As Zepbound dominates headlines as a new obesity-fighting drug, a nutritionist warns that weight loss shouldn’t be the only goal

Medications can play an important role in weight management, but not at the expense of overall nutrition. And healthy lifestyle habits are also key.

As Zepbound dominates headlines as a new obesity-fighting drug, a nutritionist warns that weight loss shouldn’t be the only goal
Business

As Lilly competition heats up, Novo CEO details strategy for new Wegovy launches

Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its

As Lilly competition heats up, Novo CEO details strategy for new Wegovy launches
World

More than a billion people worldwide are obese, WHO study finds

More than a billion people globally are now considered obese, a condition linked to an increased risk of numerous serious health problems, according to updated

More than a billion people worldwide are obese, WHO study finds
Business

Novo Nordisk hopes to launch experimental obesity drug this decade

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the

Novo Nordisk hopes to launch experimental obesity drug this decade
Business|Health|News

Medicare can pay for obesity drugs like Wegovy in certain heart patients

Certain Medicare patients may get help paying for the popular weight-loss drug Wegovy, as long as they also have heart disease

Medicare can pay for obesity drugs like Wegovy in certain heart patients
Business|Health

Amgen investors await weight-loss drug data

Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-

Amgen investors await weight-loss drug data
Health

Obesity and high blood sugar play ever growing role in ill-health, study shows

Obesity, high blood sugar and high blood pressure among other metabolic issues now lead to almost 50% more years of healthy life lost to either disease or

Obesity and high blood sugar play ever growing role in ill-health, study shows
Health

Use of Wegovy and other weight-loss drugs soars among kids and young adults

Use of diabetes and obesity medications such as Ozempic, Wegovy and other so-called GLP-1 drugs has soared among teens and young adults

Use of Wegovy and other weight-loss drugs soars among kids and young adults
Health

Wegovy users have less kidney-related health problems, analysis of Novo study finds

Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the

Wegovy users have less kidney-related health problems, analysis of Novo study finds
Health

Added health benefits of Wegovy, Zepbound could attract more men, doctors say

Evidence that weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound can cut heart disease risk, treat sleep apnea and address other health

Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Health

Weight-loss options for US youth are hard to come by

For many U.S. parents seeking help for a child with obesity, the most widely-endorsed treatment is out of reach - and it's not the popular weight-loss

Weight-loss options for US youth are hard to come by
Health|Science

Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows

Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same

Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows
Business|Health

Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing

Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular

Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing
Economy|Health

India plans incentives for diabetes, obesity drug makers in 2026, government official says

India is planning to offer incentives to promote local manufacturing of GLP-1 drugs used to treat diabetes and obesity, in 2026, a top government official said

India plans incentives for diabetes, obesity drug makers in 2026, government official says

Follow